Along those lines, myeloid-specific KO of Gasdermin D (GSDMD) boosted anti-tumor immunity in anti-PD-L1-treated B16F10 melanoma-bearing mice, as characterized by elevated infiltration of CD4+ and CD8+ T cells, but also B cells and natural killer (NK) cells. Here, CD8A is linked to melanoma.